Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A fully human effector-silent Fc immunoglobulin G1 (IgG1) trispecific antibody targeting the tumor-associated antigens (TAAs) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29) and cluster of differentiation 20 (CD20), and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD79b/CD20/CD3 trispecific antibody JNJ-80948543 targets and binds to CD79b- and/or CD20-expressing tumor B-cells and CD3 antigen on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to CD79b- and/or CD20-expressing tumor B-cells, resulting in CTL-mediated killing of tumor cells. CD79b, a critical receptor for successful B-cell development and part of the B-cell receptor (BCR) signaling complex, is widely expressed in certain subtypes of B-cell lymphomas. CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.

**Synonyms:** - Anti-CD79b/Anti-CD20/Anti-CD3 Trispecific Antibody JNJ-80948543 - CD79b/CD20/CD3 T-cell Engager JNJ-80948543 - CD79b/CD20/CD3 TCE JNJ-80948543 - JNJ 80948543 - JNJ-80948543 - JNJ80948543